Inovio Pharmaceuticals (INO) Debt Ratio (2010 - 2023)

Inovio Pharmaceuticals (INO) posted Debt Ratio of 0.1 for Q4 2023, up 14.89% sequentially from 0.09 in Q3 2023.

Inovio Pharmaceuticals (INO) Debt Ratio (2010 - 2023) Analysis & Trends

Inovio Pharmaceuticals has reported Debt Ratio for 14 years, with the latest figure at 0.1 in Q4 2023.

Quarterly Debt Ratio changed N/A year-over-year to 0.1 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 0.1 (changed N/A YoY) and the FY2023 annual result came in at 0.1, changed N/A from the prior year.
Debt Ratio grew to 0.1 in Q4 2023 per INO's latest filing, from 0.09 in the prior quarter.
Over five years, Debt Ratio peaked at 0.38 in Q2 2019 and troughed at 0.0 in Q1 2020.
A 5-year average of 0.06 and a median of 0.0 in 2019 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2019 and 2020: Debt Ratio surged 9423.36% in 2019, then tumbled 99.76% in 2020.
Over 5 years, Debt Ratio stood at 0.01 in 2019, then tumbled by 76.5% to 0.0 in 2020, then slipped by 7.23% to 0.0 in 2021, then surged by 277.2% to 0.0 in 2022, then jumped by 2253.6% to 0.1 in 2023.
According to Business Quant data, Debt Ratio over the past three periods registered 0.1, 0.09, and 0.07 for Q4 2023, Q3 2023, and Q2 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	138.92 Bn	131.07 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.91 Bn	77.91 Bn	3.93 Bn	0.05
3	Argenx Se	64.87 Bn	59.68 Bn	1.37 Bn	-
4	Moderna	58.18 Bn	53.04 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.96 Bn	36.87 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.53 Bn	28.23 Bn	992.69 Mn	-
7	BioNTech SE	27.79 Bn	9.40 Bn	668.28 Mn	0.03
8	Insmed	27.46 Bn	26.30 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.37 Bn	26.53 Bn	-	0.47
10	Inovio Pharmaceuticals	95.09 Mn	95.09 Mn	-	-

Download Data